Document is current
Any future updates will be listed below
-
Authors
Demus, Daniel https://orcid.org/0000-0002-5126-3076
Jansen, Bas C.
Gardner, Richard A.
Urbanowicz, Paulina A.
Wu, Haiyang
Štambuk, Tamara
Juszczak, Agata
Medvidović, Edita Pape
Juge, Nathalie
Gornik, Olga
Owen, Katharine R.
Spencer, Daniel I. R.
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (722095)
National Institute for Health Research
Biotechnology and Biological Sciences Research Council
Innovate UK Biocatalyst grant Glycoenzymes for Bioindustries (BB/M029042)
Health Services and Delivery Research Programme (BB/R012490/1)
- License Information
-
More Information
Article History
Received: 23 December 2020
Revised: 5 March 2021
Accepted: 11 March 2021
First Online: 25 March 2021
Declarations
:
: The authors based at Ludger Ltd work in commercializing analytical assays for use in the field of glycomics and the analysis of biopharmaceuticals. T.Š. is an employee of Genos Glycoscience Research Laboratory, which offers commercial service of glycomic analysis and has several patents in this field.
: The CroDiab study was approved by Ethics Committee of Clinical Hospital Merkur and University of Zagreb, Faculty of Pharmacy and Biochemistry, Croatia. The study was conducted in accordance with the Declaration of Helsinki.The YDX study was approved by the Oxfordshire Local Research Ethics Committee, and all subjects gave written informed consent.
